Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/53066
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKim W.S.-
dc.contributor.authorShortt J.-
dc.contributor.authorZinzani P.L.-
dc.contributor.authorMikhailova N.-
dc.contributor.authorRadeski D.-
dc.contributor.authorRibrag V.-
dc.contributor.authorDomenech E.D.-
dc.contributor.authorSawas A.-
dc.contributor.authorAlexis K.-
dc.contributor.authorEmig M.-
dc.contributor.authorElbadri R.-
dc.contributor.authorHajela P.-
dc.contributor.authorRavenstijn P.-
dc.contributor.authorPinto S.-
dc.contributor.authorGarcia L.-
dc.contributor.authorOveresch A.-
dc.contributor.authorPietzko K.-
dc.contributor.authorHorwitz S.-
dc.date.accessioned2025-01-20T00:24:52Z-
dc.date.available2025-01-20T00:24:52Z-
dc.date.copyright2025-
dc.date.issued2025-01-14en
dc.identifier.citationClinical Cancer Research. 31(1) (pp 65-73), 2025. Date of Publication: 01 Jan 2025.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/53066-
dc.description.abstractPurpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL. Patients and Methods: Patients included those with CD30 expression in >=1% of tumor cells and who were R/R following >=1 prior line of systemic therapy. Acimtamig (200 mg) was administered once weekly in 8-week cycles. The primary endpoint was the overall response rate by fluorodeoxyglucose-PET per independent review committee; secondary and exploratory endpoints included duration of response, safety, progression-free survival, and overall survival. Result(s): The overall response rate in 108 patients was 32.4% [95% confidence interval (CI), 23.7, 42.1] with a complete response rate of 10.2% (95% CI, 5.2, 17.5); the median duration of response was 2.3 months (95% CI, 1.9, 6.5). Patients with R/R angioimmunoblastic T-cell lymphoma exhibited the greatest number of responses [53.3% (95% CI, 34.3, 71.7)]. Responses were independent of CD30 expression level, prior brentuximab vedotin treatment, or steroid premedication. Acimtamig exhibited a tolerable safety profile; the most common treatment-related adverse events were infusion-related reactions in 27 patients (25.0%) and neutropenia in 11 patients (10.2%). No cases of cytokine release syndrome or acimtamig-related deaths were reported. Despite exhibiting promising clinical activity and tolerable safety in a heavily pretreated PTCL population, the study did not meet the criteria for the primary endpoint. Conclusion(s): The promising clinical efficacy observed warrants further investigation, and development of acimtamig for patients with R/R CD30+ lymphomas continues in combination with allogeneic NK cells.Copyright ©2024 The Authors.-
dc.publisherAmerican Association for Cancer Research Inc.-
dc.relation.ispartofClinical Cancer Research-
dc.subject.meshangioimmunoblastic T cell lymphoma-
dc.subject.meshcytokine release syndrome-
dc.subject.meshinfusion related reaction-
dc.subject.meshneutropenia-
dc.subject.meshperipheral T cell lymphoma-
dc.subject.meshsystemic therapy-
dc.titleA phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas.-
dc.typeArticle-
dc.identifier.affiliationHaematology-
dc.type.studyortrialClinical trial-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1158/1078-0432.CCR-24-1913-
dc.publisher.placeUnited States-
dc.identifier.pubmedid39531538-
dc.identifier.institution(Kim) Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea-
dc.identifier.institution(Shortt) Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Clayton, VIC, Australia-
dc.identifier.institution(Shortt) Monash Hematology, Monash Health, Clayton, VIC, Australia-
dc.identifier.institution(Zinzani) IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seragnoli,", Bologna, Italy-
dc.identifier.institution(Zinzani) Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna, Italy-
dc.identifier.institution(Mikhailova) Raisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, First Saint Petersburg State Pavlov Medical University, Saint Petersburg, Russian Federation-
dc.identifier.institution(Radeski) Linear Clinical Research & Sir Charles Gairdner Hospital, Perth, WA, Australia-
dc.identifier.institution(Ribrag) Institut Gustave Roussy, Villejuif, France-
dc.identifier.institution(Domenech) Institut Catala d'Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona, Spain-
dc.identifier.institution(Sawas) Columbia University Medical Center, New York, NY, United States-
dc.identifier.institution(Alexis, Garcia) Affimed Inc., New York, NY, United States-
dc.identifier.institution(Emig, Elbadri, Hajela, Ravenstijn, Pinto, Overesch, Pietzko) Affimed GmbH, Mannheim, Germany-
dc.identifier.institution(Horwitz) Memorial Sloan Kettering Cancer Center, New York, NY, United States-
dc.identifier.affiliationmh(Shortt) Monash Hematology, Monash Health, Clayton, VIC, Australia-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

26
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.